Actively Recruiting
IPGx PILOT Whole Genome Sequencing Extension Cohort
Led by Texas A&M University · Updated on 2025-01-09
50
Participants Needed
1
Research Sites
52 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The investigator's primary aim is to evaluate polypharmacy-associated adverse drug reactions (ADR) in a pilot study of at-risk patients using state-of-the-art pharmacogenomic technology and to use this information to make recommendations for optimization of pharmacotherapy regimens. The data from the pilot cohort will be used to optimize and integrate a customized electronic decision support (clinical semantic network; CSN) dashboard to identify drug regimens that should be modified, replaced, or discontinued. A secondary objective of the pilot study is to evaluate the capacity/saturation of CYP P450 enzymatic pathways in polypharmacy patients. A third objective is to determine the feasibility of the planned informatics workflows between the CLIA lab, the EMR, and the Family Medicine Practice including Whole Genome Sequencing (WGS).
CONDITIONS
Official Title
IPGx PILOT Whole Genome Sequencing Extension Cohort
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Individuals taking 5 or more medications, including over-the-counter drugs, supplements, natural products, cannabis products, or recreational drugs
- Ability to understand and provide consent
- Consent to donate urine, genetic (buccal swab), and blood samples, and undergo a full history and physical exam
- All genders eligible
- Age between 18 and 100 years
You will not qualify if you...
- Diagnosed or treated for any cancer other than basal cell cancer in the last 5 years; metastatic melanoma in last 5 years excluded
- Currently admitted to hospice care
- History of Hepatitis B or C infection
- Active liver disease or abnormal liver function tests (Meld score >10, ALT or AST >100 U/L, AST/ALT ratio >2)
- Taking imidazole antifungal medication
- Declines to participate or share medical information with staff
- Diagnosis of Alzheimer's disease or related dementias
- Pregnant individuals
- Unable or unwilling to provide consent
- Unable to verbally communicate or understand English language
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Texas A&M Family Care
Bryan, Texas, United States, 77802
Actively Recruiting
Research Team
K
Kenneth S Ramos,, MD
CONTACT
R
Rick Silva, PhD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here